Kanabo Group Reports Narrowed Pretax Loss for First Half-Year

1 Mins read

Kanabo Group, a leading medical-cannabis company, has announced a substantial reduction in its pretax loss for the first half of the year. This positive financial outcome was driven by an impressive 88% increase in revenue, largely attributed to strong sales in existing markets. In addition, the company is actively seeking expansion opportunities to further bolster its growth.

For the six months ending on June 30, Kanabo Group reported a pretax loss of £1.6 million, a significant improvement compared to the £3.8 million loss during the same period last year. Moreover, revenue experienced a substantial surge from £239,000 to £449,000.

The company also achieved a remarkable 63% reduction in operating loss, with figures dropping from £3.7 million to £1.4 million. These remarkable results reflect Kanabo Group’s relentless commitment to excellence and continuous efforts to optimize its financial performance.

Chief Executive Officer Avihu Tamir expressed enthusiasm about the company’s current position and future prospects. He stated, “We are actively exploring opportunities to expand beyond pain management into other medical fields that exhibit significant unmet demand. As we move forward, our primary objectives remain focused on increasing our patient numbers and revenue, while staying dedicated to providing personalized and accessible healthcare.”

With a firm belief in the company’s potential for both the short and medium-term, the board remains confident in Kanabo Group’s overall trajectory and strategic direction.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

9 + 1 =